Valeant (VRX) Derm Prescriptions Fell 1.5% W/W - RBC

August 22, 2016 2:41 PM EDT
Get Alerts VRX Hot Sheet
Price: $15.08 -3.52%

Rating Summary:
    11 Buy, 11 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade VRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

RBC Capital offerd its weekly prescription tracker for Valeant Pharma (NYSE: VRX) today. The firm rates Valeant at Sector Perform with a price target of $36.

Douglas Miehm noted the following:

  • NRx Derm products down 1.5% WoW. For the week ending August 12th, new derm scripts (NRx) were down 1.5% vs. up 0.2% the prior week. NRx in the week were 50,246, down slightly from 50,992 the prior week. Derm TRx were down 1.3% WoW vs. up 0.2% the prior week. TRx were 71,963 vs. 72,876 the prior week. Exhibit 1 outlines derm script trends. We continue to closely watch derm TRx/NRx trends to assess whether the recently implemented co-pay increases (outlined in our Q2/16 Results note) have an impact on scripts that run through the Walgreens program.
  • NRx Ophth products decreased 0.7% WoW. For the week ending August 12th, new ophth scripts (NRx) were down 0.7% WoW vs. down 1.0% the prior week. NRx were 42,487 vs. 42,783 the prior week. Ophth TRx were down 1.5% WoW to 56,129 TRx vs. down 0.1% the prior week. Symphony Health data shows ophth NRx down 0.3% WoW and TRx decreasing 1.3% WoW. Exhibit 2 outlines ophth script trends.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

RBC Capital

Add Your Comment